Future Directions of Compound Management Field Require Further Evolution of Drug Discovery Processes

Pharma IQ News

PHILADELPHIA, PA  – Pharma IQ, a division of IQPC, announces the 7th Annual Compound Management & Integrity Summit, being held September 26 to 30, 2011 in Philadelphia.  Industry leaders taking part in the Summit offer perspectives on future directions of the compound management & integrity (CMI) field, case studies and best practices within the industry.

As drug discovery becomes increasingly complex and costs for developing a drug increase, having a well organised, efficient and low-cost compound management strategy to continuously support the drug discovery pipeline is essential.  The role of Clinical Research Organisations (CROs) in the drug discovery process is ever-increasing and constantly evolving, and as data management and distribution efforts improve, there is increased opportunity for leveraging CROs within drug discovery research.

The 7th Compound Management & Integrity Summit investigates the internal function of compound management & integrity strategies currently used within the pharmaceutical and biotechnology industries, and examines future directions of the CMI field, using case study examples from industry leaders and benchmark best practices. Speakers from Pfizer, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Merck & Co., Inc. GlaxoSmithKline investigate topics that include:

For more information on the Summit, please visit www.compoundmanagementsummit.com or contact Robert Littlefield, Program Director at Robert.Littlefield@iqpc.com.

About IQPC
IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Sydney, and Toronto.

Ashley Rowe
T: +1 646-*
F: +1 888-231-7864